

AMENDMENTS

Amendment to the Specification:

At page 10, please replace the paragraph beginning on line 13 with the following substitute paragraph:

FIG. 1 illustrates an exemplary phenobarbital-responsive enhancer module (PBREM) and description of polymorphisms (SEQ ID NO:14). The previously described PBREM domains are underlined with the NR half-site sequences shown in bold. The polymorphic sites of the present application are included. The variants found at these sites are also listed. Positions indicated are from the first base of the *UGT1A* cluster sequence (Genbank accession No. AF297093) (SEQ ID NO:1).

At page 23, please replace the paragraph beginning on line 9 with the following substitute paragraph:

Pairs of primers designed to selectively hybridize to nucleic acids corresponding to the *UGT1* gene locus (Genbank accession ~~AF279093~~–AF297093), *UGT1A1* gene and/or SEQ ID NO:1 or variants thereof, and fragments thereof are contacted with the template nucleic acid under conditions that permit selective hybridization. SEQ ID NO:1 set forth a nucleotide sequence that includes a majority of the *UGT1A1* gene. SEQ ID NO:1 includes nucleotides 169,831 to 187,313 of the *UGT1* gene locus with nucleotide 1645 of SEQ ID NO:1 corresponding to nucleotide –3565 from the transcriptional start of the *UGT1A1* gene, thus the transcriptional start is located at nucleotide 5212 of SEQ ID NO:1. Depending upon the desired application, high stringency hybridization conditions may be selected that will only allow hybridization to sequences that are completely complementary to the primers. In other embodiments, hybridization may occur under reduced stringency to allow for amplification of nucleic acids that contain one or more mismatches with the primer sequences. Once hybridized, the template-primer complex is contacted with one or more enzymes that facilitate template-dependent nucleic acid synthesis. Multiple rounds of amplification, also referred to as "cycles," are conducted until a sufficient amount of amplification product is produced.

Please delete the Sequence Listing and insert therefor the substitute Sequence Listing submitted concurrently herewith as text through EFS-Web.